D’Arcy, B. M., Swingle, M. R., Papke, C. M., Abney, K. A., Bouska, E. S., Prakash, A., & Honkanen, R. E. (2019). The Antitumor Drug LB-100 is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active Site Catalytic Metals in PPP5C. Mol Cancer Ther.
Chicago Style CitationD’Arcy, Brandon M., Mark R. Swingle, Cinta M. Papke, Kevin A. Abney, Erin S. Bouska, Aishwarya Prakash, and Richard E. Honkanen. "The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating With the Active Site Catalytic Metals in PPP5C." Mol Cancer Ther 2019.
MLA CitationD’Arcy, Brandon M., et al. "The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating With the Active Site Catalytic Metals in PPP5C." Mol Cancer Ther 2019.